Frontlight ResearchEarly access
CompletedNo phase
Effectiveness and Safety of Partition Multi-point Defocused Myopia Management Spectacle Lens in Myopia Control
Key facts
- Who runs it
- Zhongshan Ophthalmic Center, Sun Yat-sen University
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 194 people enrolled
- Started
- 20 Mar 2023
- Ended
- 27 May 2025
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Partition defocus myopia management spectacle lens
- Spectacle lenses with aspherical lenslets
- Record updated
- 12 March 2026
Who can take part
- Age
- 8 years to 13 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 14 criteriaShow less
Who can take part
- Aged 8 to 13 years
- Under the condition of bilateral cycloplegic autorefraction, the spherical refractive error of -0.75 to -4.75 D in each eye and astigmatism of not more than 1.50 D and anisometropia of not more than 1.00 D
- Best-corrected visual acuity of equal or better than 0.00 LogMAR (>= 1.0 as Snellen)
- The intraocular pressure of 10 to 21mmHg
- Volunteer to participate in this clinical trial with signature of the informed consent form
Who cannot take part
- Participation of the drug clinical trial within three month and the device clinical trial within one month
- Participation of any myopia control clinical research trial within three months, and currently using rigid contact lenses (including nursing products), multifocal contact lenses, progressive multifocal lenses and other specially designed myopia control lenses, atropine drugs, etc
- History of eye injury or intraocular surgery
- Ocular disease, such as uveitis and other inflammatory diseases, glaucoma, cataract, fundus diseases, eye tumors, dominant strabismus, and any eye diseases that affect visual function
- Systemic diseases causing low immunity (such as diabetes, Down's syndrome, rheumatoid arthritis, psychotic patients or other diseases that researchers think are not suitable for wearing glasses)
- Clinically abnormal slit-lamp findings
- Abnormal fundus examination
- Only one eye meets the inclusion criteria
- Unable to have regular follow-up
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Myopia is considered to be the most common type of refractive error, and the incidence of myopia has shown a trend of low age. Recent studies found that the new aspheric microlens spectacle lens can more effectively control the progress of diopter than the single-vision spectcale lens. A new technology of equivalent defocusing around the lens called the partition multi-point defocus optical technology is adopted in this study.
The 2 groups in the trial
- Intervention groupTreatment being tested
The participants wear the partition defocus myopia management spectacle lens.
Treatment: Partition defocus myopia management spectacle lens
- Control groupExisting treatment, for comparison
spectacle lenses with aspherical lenslets
Treatment: Spectacle lenses with aspherical lenslets
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Effectiveness and Safety of Partition Multi-point Defocused Myopia Management Spectacle Lens in Myopia Control Compared With Spectacle Lenses With Aspherical Lenslets: a Randomised Non-inferiority Trial
- Record updated
- 12 March 2026